These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35602580)

  • 21. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A useful design utilizing the information fraction in a group sequential clinical trial with censored survival data.
    Hsu CY; Chen CH; Hsu KN; Lu YH
    Biometrics; 2019 Mar; 75(1):133-143. PubMed ID: 30004574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Group sequential methods for interim monitoring of randomized clinical trials with time-lagged outcome.
    Tsiatis AA; Davidian M
    Stat Med; 2022 Dec; 41(28):5517-5536. PubMed ID: 36117235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adaptive multiarm multistage clinical trials.
    Ghosh P; Liu L; Mehta C
    Stat Med; 2020 Apr; 39(8):1084-1102. PubMed ID: 32048313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conditional bias of point estimates following a group sequential test.
    Fan XF; DeMets DL; Lan KK
    J Biopharm Stat; 2004 May; 14(2):505-30. PubMed ID: 15206542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study.
    Bayar MA; Le Teuff G; Koenig F; Le Deley MC; Michiels S
    Stat Methods Med Res; 2020 Jun; 29(6):1483-1498. PubMed ID: 31354106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The application of bespoke spending functions in group-sequential designs and the effect of delayed treatment switching in survival trials.
    Stone A
    Pharm Stat; 2010; 9(2):151-61. PubMed ID: 19771540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of methods for futility stopping based on conditional power.
    Lachin JM
    Stat Med; 2005 Sep; 24(18):2747-64. PubMed ID: 16134130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
    Levin GP; Emerson SC; Emerson SS
    Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fitting spending functions.
    Anderson KM; Clark JB
    Stat Med; 2010 Feb; 29(3):321-7. PubMed ID: 19842091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Group sequential large sample T2-like chi2 tests for multivariate observations.
    Lachin JM; Greenhouse SW; Bautista OM
    Stat Med; 2003 Nov; 22(21):3357-68. PubMed ID: 14566920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asymptotic properties of maximum likelihood estimators with sample size recalculation.
    Tarima S; Flournoy N
    Stat Pap (Berl); 2019 Apr; 60(2):373-394. PubMed ID: 31827313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A general statistical principle for changing a design any time during the course of a trial.
    Müller HH; Schäfer H
    Stat Med; 2004 Aug; 23(16):2497-508. PubMed ID: 15287080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimation After a Group Sequential Trial.
    Milanzi E; Molenberghs G; Alonso A; Kenward MG; Tsiatis AA; Davidian M; Verbeke G
    Stat Biosci; 2015 Oct; 7(2):187-205. PubMed ID: 26478751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes.
    Sugimoto T; Hamasaki T; Evans SR; Halabi S
    Lifetime Data Anal; 2020 Apr; 26(2):266-291. PubMed ID: 30980317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An adaptive two-arm clinical trial using early endpoints to inform decision making: design for a study of sub-acromial spacers for repair of rotator cuff tendon tears.
    Parsons N; Stallard N; Parsons H; Wells P; Underwood M; Mason J; Metcalfe A
    Trials; 2019 Dec; 20(1):694. PubMed ID: 31815651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.